We are a private limited liability company incorporated in 2013 in Uganda to provide services, which include those in the field of medical concerns.

Our vision is to be the leading biotechnology company, providing forever-lasting solutions to problems of medical, veterinary, industrial, agricultural, and environmental significance.

Our mission is to enhance biological research in areas of medical, veterinary, industrial, agricultural and environmental significance by providing new methods that permit quick detection of problems, and give solutions that are cheap, effective, and of minimal, if any, negative effects.

For more than four decades now, HIV pandemic has continued to torture the world. Cancer, on the other hand, has been a problem for millennia. Hepatitis B virus, though on a small scale compared to HIV, has been a persistent problem. More recently Covid-19 threatened man’s existence on planet earth. For eleven years now we have been working on developing therapeutics to quell these diseases, that of covid-19 being the most recent of our developments.

Our four prototypes are candidate cures; BertoV1 for HIV, BertoCAN for cancer, BertoHEP for hepatitis B, and BertoCOV for covid-19. The advantages that our enzyme-based therapies have over other forms of treatments for these diseases are that; 1) they are designed to be single dose and effectiveness is guaranteed irrespective of the severity of the disease, 2) treatment failure is abated because of the high specificity of these enzymes, 3) side effects are negligible, and 4) quick recovery is guaranteed.

Advancing this work to make the prototypes eligible for clinical trials require publications of our science on each of them. It is for this reason that we are looking for a seed investment of Seventy Thousand (70,000) Euros to cover the publication fees and also upgrade our current laboratory infrastructure. In exchange for this funding, we shall issue out shares in our company. These publications once complete will serve as proof of concept, which is very important in the subsequent stages.

Currently, Uganda manufactures antiretroviral drugs for HIV and is the sole supplier of East, Central and Southern Africa. In May 2023 his excellency the president signed into law a bill that is widely seen by donors to be anti-LGBTQ and the said donors have threatened to withdraw their funding for services, among which HIV and cancer treatments are included. This situation will make the population embrace our work, and as such a huge market awaits our products. Furthermore, the stigma associated with being HIV positive, and the pain of suffering from cancer, will make our products sell.

We have no intention of exiting the market, instead we hope to stamp our presence in the biopharmaceutical industry by developing products that match the current market trends, giving value to our investors and customers. This step that we are already making will help us develop a network in the biopharmaceutical ecosystem and as such will always be relevant.

At the moment the business being run by its two co-founders.

Business model:

We are a pre-revenue biotech that has options of going business-to-business with the pharmaceutical manufacturers or business-to-consumer, depending on the path that works in the best interest of our investors.

USP’s:

Our prototypes have the following qualities

• Single dose, one-off treatment.
• Quick acting, results within 28 days (2 days for covid-19).
• Negligible, if any, side effects.
• Easy to consume.
• Easy to store.
• Long shelf life.
• We are pioneers in this science.
• Potential customers like what we are doing and are eagerly waiting for the products.

Investment need:

• 25,000 Euros will be required to refurbish laboratory infrastructure.
• 45,000 Euros will be used to publish our scientific findings.

Experience founder(s):

Profile of Fouder 1:

• A graduate of bachelor of science technology (biology) – Kyambogo University – is our chief executive officer, chief scientist, co-founder and director. His eleven years of laboratory practice has yielded expertise in proteomics, nucleic acid techniques, and general research. Currently has one hundred thirty-four manuscripts to publish in biological science disciplines that cut across biochemistry, bacteriology, virology, histopathology and physiology, and chemistry. Designing enzymes for specific therapeutic purposes, with adaptations for various routes of administration, is a skill he prides in.
• He has been in the education sector for a cumulative total of three years now and has developed a lot of skill and experience in people training, evaluation and management; organizational management; project design, implementation, monitoring, and evaluation.
• He is fully acquainted with the regulatory frameworks, locally and internationally, that govern the development of biopharmaceutical products, right from performing laboratory experiments to conducting clinical trials on human subjects.
• He is a pragmatic leader that approaches situations with open-mindedness and calmness, which results in effective solutions raised for whatever problems arise; and a good reader of environmental trends, which leads to better planning and consequently better strategies that are vital not just for beating the competition but for long term survival of the business.
• In 2020 when he was arrested over the claims of these prototypes, he made it on record that the claims could be verified scientifically. This drew a lot of support from other scientists and sympathizers.

Other relevant information:

We are a pre-revenue biotech. We have so far invested 30,000 Euros and are hoping to raise 70,000 Euros to advance our work.